AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$PCVX

Cowan Elvia sold $1.6M of PCVX

Cowan Elvia (SVP, Finance & CAO) sold 19,000 shares of Vaxcyte, Inc. (PCVX) at $86.74 ($1.65M total) on 2026-10-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cowan Elvia
Published Oct 7, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 8:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PCVX
Bearish
medium confidence
Mentioned
$PCVX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PCVXBearishLow
01

Why it matters

The disclosed sale adds new information about insider activity, but its modest size limits market impact.

02

Market read

Primary insider sale filing; modest pressure expected on PCVX.

03

What to watch

Potential upcoming financing or dilution events not disclosed.

Relevance 5/10Novelty 5/10Timing: today

Background

SEC Form 4 filing provides the first public disclosure of the insider transaction.

Company-level read

Ticker impact

$PCVXBearishMedium confidence
Context

Form 4 disclosed a $1.65M open‑market sale of 19,000 shares by SVP of Finance, indicating insider divestment.

Expected impact

likely modest pressure as the market prices the insider sell.

Evidence & confidence

The sale size is modest relative to market cap, but insider selling often prompts short‑term downside bias.

Market effects

Sector

Minimal impact on the broader biotech sector.

Regional

No significant regional effect.

Global

Limited to Vaxcyte shareholders.

Counterpoint

What could challenge this read

The sale could be routine portfolio rebalancing, not a bearish signal.

Key entities

  • Insider
    Cowan Elvia

    SVP, Finance & CAO at Vaxcyte, reporting the sale.

  • Company
    Vaxcyte, Inc.

    Biotech firm developing vaccine technologies.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PCVX insider trading history →

Related articles

$PCVXHighAI 9/10

Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update

Vaxcyte, Inc. (PCVX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well Tolerated and Demonstrated a Safety P

SEC EDGAR 8-K
$PCVXHighAI 8/10

Vaxcyte’s vaccine candidate met every main goal in a trial of 4,047 adults. More trial results are expected in 2027.

Vaxcyte's VAX-31 vaccine met all primary endpoints in a Phase 3 trial of 4,047 adults, showing safety and efficacy. The company plans to report more trial results in 2027 and submit a BLA in 2028. VAX-31 is designed to prevent pneumococcal disease. Vaxcyte also announced progress in its VAX-A1 vaccine candidate for Group A Streptococcus.

stocktitan.net
$PCVXHighAI 9/10

Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update

Vaxcyte reported Q3 2026 results, highlighting positive topline data from the OPUS-1 Phase 3 trial of VAX-31, meeting all primary endpoints. The company expects results from OPUS-2 and OPUS-3 trials in early 2027, supporting a BLA submission in 2028. Vaxcyte also announced progress in its VAX-31 infant indication and VAX-A1 Phase 1 study. As of September 30, 2026, the company had $3.4 billion in cash and investments.

globenewswire.com